Maxim Group analyst Jason McCarthy maintained a Buy rating on Biocept Inc (BIOC) today and set a price target of $3. The company’s shares closed yesterday at $1.18, close to its 52-week low of $0.66.
McCarthy observed:
“Biocept reported 4Q18 and YE-2018 with revenue of $0.86M and $3.3M, respectively, and a net loss of ($6M) and ($25.2M), respectively. The company currently has ~$15M in cash on the balance sheet.”
According to TipRanks.com, McCarthy has currently no stars on a ranking scale of 0-5 stars, with an average return of -8.3% and a 29.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Adial Pharmaceuticals Inc.
Biocept Inc has an analyst consensus of Moderate Buy, with a price target consensus of $3.
See today’s analyst top recommended stocks >>
The company has a one-year high of $12.15 and a one-year low of $0.66. Currently, Biocept Inc has an average volume of 3.25M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample.
